SC 13G: BRAINSTORM CELL THERAPEUTICS INC.
Ticker: BCLI · Form: SC 13G · Filed: Nov 13, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | SC 13G |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by BRAINSTORM CELL THERAPEUTICS INC..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Brainstorm Cell Therapeutics Inc. (ticker: BCLI) to the SEC on Nov 13, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
How long is this filing?
Brainstorm Cell Therapeutics Inc.'s SC 13G filing is 3 pages with approximately 914 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 914 words · 4 min read · ~3 pages · Grade level 7.8 · Accepted 2024-11-13 07:55:51
Filing Documents
- mruckBCLI1112.htm (SC 13G) — 25KB
- 0001980840-24-000001.txt ( ) — 27KB
(a)
ITEM 1(a). NAME OF ISSUER: Brainstorm Cell Therapeutics Inc.
(b)
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 1325 Avenue of Americas, 28th Floor, New York, NY 10019
(a)
ITEM 2(a). NAME OF PERSON FILING: Matthew J. Ruck
(b)
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 9711 Washingtonian Blvd, Suite 550, Gaithersburg, MD 20878
(c)
ITEM 2(c). CITIZENSHIP: Gaithersburg, Maryland, United States
(d)
ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock
(e)
ITEM 2(e). CUSIP NUMBER: 10501E300 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c); (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution: ITEM 4. (a) Amount beneficially owned: 275,838 (b) Percent of class: 5.18% (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: Matthew J. Ruck :275,838 (ii) shared power to vote or to direct the vote: Matthew J. Ruck : 0 (iii) sole power to dispose or direct the disposition of: Matthew J. Ruck :275,838 (iv) shared power to dispose or to direct the disposition of: Matthew J. Ruck : 0 ITEM 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the bene